NCT07763834
Uromodulin as a Biomarker in Lupus Nephritis
Not Yet Recruiting · Not specified · Assiut University · registry updated 2026-08-13
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
Evaluation of Uromodulin as a biomarker of renal histological activity/ Chronicity indices in lupus nephritis
Inclusion
- Group I: 30 patients with different classes of Lupus Nephritis. These cases are biopsy proven
- LN. Histological diagnosis of LN is according to the revised International Society of
- Nephrology/ Renal Pathology Society (ISN/RPS) classification and modified National Institute of Health (NIH) activity and chronicity indices (Bajema et al 2018) .
- Biopsy-proven lupus nephritis at the time of uromodulin blood sampling.
- Group II: 10 patients with active SLE without renal involvement and with SLEDAI score ≥6
- Group III: 10 patients with non-active SLE with SLEDAI score \<6
Exclusion
- Pregnancy or lactation
- AKI secondary to pre renal OR post renal cause (from clinical history and imaging).
- End-stage renal disease requiring dialysis
- Active infection or sepsis
- Active malignancy (either under treatment or within 5 years of successful treatment)
- History of renal transplantation